# US 2021/0061874 A1 · Claudin-6 peptides

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2021/0061874 A1
- Document ID: US20210061874A1
- Status: Published application
- Kind: A1
- Application number: 17/017,444
- Filed: 2020-09-10
- Published: 2021-03-04
- Earliest claimed: 2016-04-29
- Applicants: Immunocore Limited; Adaptimmune Limited
- Inventors: Alex POWLESLAND; Mei SUN
- Web page: https://patentgrep.com/patent/US20210061874A1

## CPC

- C07K 14/705: Receptors; Cell surface antigens; Cell surface determinants {(tumour specific antigens C07K14/4748)}
- A61P 35/00: Antineoplastic agents
- C07K 14/4748: {Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE}
- C07K 14/7051: {T-cell receptor (TcR)-CD3 complex}
- C07K 14/70539: {MHC-molecules, e.g. HLA-molecules}
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- G01N 33/575: for cancer
- G01N 33/5759: {involving compounds localised on the membrane of tumour or cancer cells}
- G01N 33/6878: {in epitope analysis}
- A61K 38/00: Medicinal preparations containing peptides (peptides containing beta-lactam rings A61K31/00; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, A61K31/00; ergot alkaloids of the cyclic peptide type A61K31/48; containing macromolecular compounds having statistically distributed amino acid units A61K31/74; medicinal preparations containing antigens or antibodies A61K39/00; medicinal preparations characterised by the non-active ingredients, e.g. peptides as drug carriers, A61K47/00)
- G01N 2333/70539: MHC-molecules, e.g. HLA-molecules
- G01N 2500/02: Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)

## Abstract

The present invention relates to novel peptides derived from Claudin-6 (CLDN6), complexes comprising such peptides bound to recombinant MHC molecules, and cells presenting said peptide in complex with MHC molecules. Also provided by the present invention are binding moieties that bind to the peptides and/or complexes of the invention. Such moieties are useful for the development of immunotherapeutic reagents for the treatment of diseases such as cancer.

## Claims

### Claim 1

A polypeptide comprising:
(i) the amino acid sequence SLLALPQDLQA (SEQ ID NO: 1);
(ii) the amino acid sequence VLTSGIVFV (SEQ ID NO: 2);
(iii) the amino acid sequence TLIPVCWTA (SEQ ID NO: 3);
(iv) the amino acid sequence AISRGPSEYPTKNYV (SEQ ID NO: 4);
(v) the amino acid sequence GLLLLGGGL (SEQ ID NO: 5); or
(vi) the amino acid sequence of SEQ ID NOs: 1-5 with the exception of 1, 2 or 3 amino acid substitutions, and/or 1, 2 or 3 amino acid insertions, and/or 1, 2 or 3 amino acid deletions,
wherein the polypeptide is capable of forming a complex with a Major Histocompatibility Complex (MHC) molecule.

### Claim 2 (depends on 1)

The polypeptide of claim 1, wherein the polypeptide consists of from 8 to 16 amino acids.

### Claim 3 (depends on 1)

The polypeptide of claim 1, wherein the polypeptide consists of the amino acid sequence of any one of SEQ ID NOs 1-5

### Claim 4 (depends on 1)

A complex of the polypeptide of claim 1 and a Major Histocompatibility Complex (MHC) molecule.

### Claim 5 (depends on 4)

The complex of claim 4, wherein the MHC molecule is MHC class I

### Claim 6 (depends on 1)

A nucleic acid molecule that encodes the polypeptide as defined in claim 1.

### Claim 7 (depends on 6)

A vector comprising the nucleic acid molecule as defined in claim 6.

### Claim 8 (depends on 7)

A cell comprising the vector as claimed in claim 7.

### Claim 9 (depends on 1)

A binding moiety that binds the polypeptide of claim 1.

### Claim 10 (depends on 9)

The binding moiety of claim 9, capable of specifically binding the polypeptide when it is in complex with WIC.

### Claim 11 (depends on 10)

The binding moiety of claim 10, wherein the binding moiety is a T cell receptor (TCR) or an antibody.

### Claim 12 (depends on 11)

The binding moiety of claim 11, wherein the binding moiety is a TCR.

### Claim 13 (depends on 9)

A method of treating or preventing a disease in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a binding moiety as defined in claim 9.

### Claim 14 (depends on 13)

The method of claim 13 wherein the disease is cancer.

### Claim 15 (depends on 9)

A pharmaceutical composition comprising binding moiety as defined in claim 9 and a pharmaceutically acceptable carrier.

### Claim 16 (depends on 4)

A method of identifying a binding moiety that binds the complex as defined in claim 4, the method comprising contacting a candidate binding moiety with the complex and determining whether the candidate binding moiety binds the complex.

### Claim 17 (depends on 2)

The polypeptide of claim 2, wherein the polypeptide consists of 9 to 15 amino acids.

### Claim 18 (depends on 4)

The complex of claim 4, wherein the complex further comprises a biotin tag.

### Claim 19 (depends on 11)

The binding moiety of claim 11, wherein the binding moiety is an antibody.

### Claim 20 (depends on 12)

The binding moiety of claim 12, wherein the TCR is on the surface of a cell.
